Cartesian Therapeutics Announced Topline Results From Its Phase 2B Trial Of Descartes-08 In Patients With Generalized Myasthenia Gravis, Trial Met The Primary Endpoint With Statistical Significance
Portfolio Pulse from Benzinga Newsdesk
Cartesian Therapeutics announced positive topline results from its Phase 2B trial of Descartes-08 in patients with generalized myasthenia gravis. The trial met its primary endpoint with statistical significance, showing a 71% improvement in MGC score at Month 3 for treated patients compared to 25% for placebo. The company plans to hold an End-of-Phase 2 meeting with the FDA by year-end.
July 02, 2024 | 10:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cartesian Therapeutics' Phase 2B trial of Descartes-08 in myasthenia gravis patients met its primary endpoint with statistical significance. 71% of treated patients showed improvement vs. 25% for placebo. The company plans to hold an End-of-Phase 2 meeting with the FDA by year-end.
The positive results from the Phase 2B trial and the upcoming FDA meeting are likely to boost investor confidence in RNAC, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100